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The incidence of lung cancer has markedly increased in the past
few decades and is still increasing in many countries worldwide.
Lung cancer is a leading cause of death in many developed
countries, and approximately 140000 new cases are identified each
year in the US alone (Green, 2004). The majority of patients with
non-small-cell lung cancer (NSCLC) are diagnosed with advanced
disease and cannot undergo radical surgical treatment. Typically,
patients from this large group are offered best supportive care or
palliative treatment regimens incorporating various combinations
of chemotherapy and radiotherapy.
Progress in palliative care for lung cancer has been slow;
however, advances have been made due to better utilisation of
drugs (i.e. timing, duration of treatment), choice of drugs for first-
line therapy and subsequent regimens, and optimal combination
and timing with radiation therapy (Spiro and Porter, 2002).
Chemotherapy or chemoradiation therapy is the treatment of
choice for unresected lung cancer in many countries (Spiro and
Porter, 2002) and may be accepted as a treatment option for
resected lung cancer in the future (Arriagada et al, 2004). There is
the general agreement that properly used chemotherapy regimens
have increased life expectancy and improved the quality of life of
patients with lung cancer.
However, chemotherapy benefits can be at the expense of
adverse effects in different organ systems, including the lung
(Foucher et al, 2003; Limper, 2004). Several novel compounds,
such as irinotecan (Masuda et al, 1992; Foucher et al, 2003),
gemcitabine (Pavlakis et al, 1997), paclitaxel (Goldberg and
Vannice, 1995) and docetaxel (Merad et al, 1997), have been
associated with the development of sometimes severe lung disease
in about 3–5% of patients with lung cancer (Kunitoh et al, 1996;
Merad et al, 1997; Wang et al, 2001; Erasmus et al, 2002; Lilly,
2003). The assessment of drug causality in patients with lung
cancer who develop interstitial lung disease (ILD) is difficult
compared with other respiratory reactions to drugs. The diagnosis
of drug-associated lung disease is against the background of the
underlying neoplastic lung disease, adverse effects of other drugs,
colony-stimulating factors, oxygen or radiation therapy and
opportunistic infections. Patients with lung cancer are often
sequentially exposed to different chemotherapy regimens and the
risk of drug-induced disease may increase correlatively. Clarifying
the respective role of these factors is often impossible.
Gefitinib (‘Iressa’) is a new type of targeted treatment for
NSCLC. It is an inhibitor of the epidermal growth factor receptor
(EGFR) signalling pathway that acts intracellularly at the level of
the EGFR tyrosine kinase. Two phase II monotherapy trials
(‘Iressa’ Dose Evaluation in Advanced Lung cancer [IDEAL] 1 and
2) have reported unprecedented antitumour activity and symptom
relief in pretreated patients with advanced metastatic NSCLC
(Fukuoka et al, 2003; Kris et al, 2003). Furthermore, recent
evidence in patients with NSCLC points to a specific gain in
function in patients who bear somatic mutations in the tyrosine
kinase domain of the EGFR (Lynch et al, 2004; Paez et al, 2004).
These mutations exert a dominant oncogenic effect that correlates
with the clinical response to gefitinib, contrasted with the low
response rate seen in patients lacking these mutations (Lynch et al,
2004; Paez et al, 2004). However, in addition to patients with a
clinical response, an additional 35% of patients experience stable
disease or symptom improvement with gefitinib (Fukuoka et al,
2003; Kris et al, 2003) and further molecular studies are clearly
required to identify predictive markers in this group of patients.
The prevalence of this mutation is also different in Japanese
NSCLC patients, as opposed to NSCLC patients from the US (Paez
et al, 2004), which may explain the greater response rate of
Japanese patients to gefitinib.
Although gefitinib is not associated with many of the general
adverse effects of broadly acting cytotoxic chemotherapeutic
agents, recent reports from Japan have indicated that a proportion
of patients treated with gefitinib experienced severe ILD (Ieki et al,
2003; Inoue et al, 2003; Okamoto and Suga, 2003; Rabinowits et al,
2003; Sumter et al, 2003). Evaluation of drug causality is also
difficult here. Tolerability data from the compassionate use of
gefitinib in the ‘Iressa’ Expanded Access Programme support the
favourable safety profile reported in phase I and II trials, and
incidence figures for ILD in the West are not dissimilar to those
reported for gefitinib- vs placebo-exposed patients with NSCLC
(Giaccone et al, 2002; Herbst et al, 2004). Whether the mutations of
the EGFR signalling domain referred to above also modulate the
occurrence of adverse pulmonary effects of gefitinib, or interfere
with repair processes of the pulmonary epithelium (Suzuki et al,
2003), is unknown at this time.
This experience of ILD in patients with NSCLC has posed a
number of important questions relating to definition, diagnosis,
management and mechanisms. A group of experts in the field of
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in Seattle in May 2003. The content of the presentations is discussed
within this supplement. Hopefully, the knowledge of gefitinib may
provide new insights into the field of ILD and chemotherapy-
associated lung disease in the way it has in the treatment of cancer.
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